April 29 (Reuters) - The U.S. Food and Drug Administration (FDA) on Monday published the final rule to ensure safety and effectiveness of laboratory developed tests (LDTs), which are designed, manufactured and used within a clinical laboratory. (Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli)
Laboratory Corporation of America Holdings
Equities
LH
US50540R4092
Healthcare Facilities & Services
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
206.8 USD | -1.79% | -1.68% | -9.00% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
206.8 USD | -1.79% | -1.68% | 17.75B | ||
144.2 USD | -0.12% | +2.41% | 16.03B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.00% | 17.75B | |
+20.09% | 84.56B | |
-27.30% | 72.41B | |
+2.04% | 27.73B | |
-1.14% | 17.11B | |
+4.56% | 16.03B | |
+69.72% | 13.07B | |
+6.66% | 12.91B | |
+73.30% | 12.55B | |
+34.53% | 12.26B |
- Stock Market
- Equities
- LH Stock
- News Laboratory Corporation of America Holdings
- US FDA publishes final rule for laboratory developed tests